Relmada Therapeutics, Inc. (RLMD) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Oramed Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc.

MediWound Ltd.

Ocugen, Inc.

Esperion Therapeutics, Inc.

ProQR Therapeutics NV

DiaMedica Therapeutics, Inc.

Abeona Therapeutics, Inc.

Milestone Pharmaceuticals, Inc.

MediciNova, Inc.

Relmada Therapeutics, Inc.

Why is Relmada Therapeutics, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Relmada Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Relmada Therapeutics, Inc.

44.4%

0.21

176.60%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-182.61%

EBIT to Interest (avg)

-97.65

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.21

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

45.72%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.23

EV to EBIT

-0.01

EV to EBITDA

-0.01

EV to Capital Employed

-0.14

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-337.88%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company

DEBT-EQUITY RATIO (HY)

Lowest at -129.28 %

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

OPERATING PROFIT(Q)

Highest at USD -10.22 MM

PRE-TAX PROFIT(Q)

Highest at USD -9.85 MM

NET PROFIT(Q)

Highest at USD -9.85 MM

EPS(Q)

Highest at USD -0.3

-3What is not working for the Company

ROCE(HY)

Lowest at -175.12%

CASH AND EQV(HY)

Lowest at USD 47.68 MM

Here's what is working for Relmada Therapeutics, Inc.

Debt-Equity Ratio

Lowest at -129.28 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Operating Profit

Highest at USD -10.22 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Pre-Tax Profit

Highest at USD -9.85 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD -9.85 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD -0.3

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Relmada Therapeutics, Inc.

Cash and Eqv

Lowest at USD 47.68 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents